Dr. Reddy's Generic Metformin & Saxagliptin Hydrochloride Receives Approval in the U.S.
Sun Pharm`s Generic Saxagliptin HCL Receives Tentative Approval In Us
Merck ($MRK) intended its new weekly diabetes treatment, Marizev, to build on the success of its blockbuster DPP-4 inhibitor Januvia. But at least when it comes to safety, Marizev is lagging behind, a new report finds.
The tense battle between drug makers and patient advocates over patents and access to medicines is moving to a new venue. The latest clash is taking place in Colombia, where a government committee late last month recommended that a compulsory license should be issued for the Gleevec cancer treatment sold by Novartis.
Makers of a new class of diabetes drugs, SGLT2 inhibitors, seemed to catch a break last week when the FDA laid out a new safety warning for drugs in a competing class. But now one of the SGLT2 drugs, Johnson & Johnson's ($JNJ) hot-selling Invokana, is facing its own hurdle after the FDA said it was adding a warning for the risk for bone fractures and concerns about decreased bone density to its label.
A class of diabetes drugs that include Merck & Co Inc's Januvia have been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday.
India has decided against giving the compulsory licence for Anglo-Swedish drugmaker AstraZeneca's key antidiabetes compound Saxagliptin sought by Hyderabad-based Lee Pharma.
The Delhi High Court has dismissed AstraZeneca's plea to block Hyderabad based Lee Pharma from making copies of its anti-diabetes drug Onglyza and left it for the patent office to decide whether to grant a compulsory licence for the medicine.
AstraZeneca, Dr Reddy`s ink diabetes drug distribution pact
AstraZeneca`s Onglyza `Mortality` Risks Noted By FDA Reviewers